Engflag

Otipax L

Quick links to important sections

Otipax L

Otipax L_EN

Method of action: Anesthetic, Antiarrhythmic, Antipruritics, Incl. Antihistamines, Anesthetics, Etc, Local Anesthetic, Lubricating

Treatment option: Pain, Infection, Neuralgia, Neuropathic Pain, Shingles

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Otipax L

Otipax L is a non-systemic pharmaceutical solution formulated for local application in the ear. It is broadly defined as an Otic Preparation that utilizes a combination of active substances for localized comfort.

Property Description
Active ingredients Lidocaine Hydrochloride, Phenazone
Form Otic Solution (Ear Drops)
Pharmacological class Analgesic and Local Anesthetic
Route of administration Topical (Otological)
Origin Synthetic Combination Product

Composition and Identity: What Kind of Drug is Otipax L?

Otipax L is a combination product classified as an Analgesic and Local Anesthetic specifically for otological use, reflecting the medicine's dual action profile. This formulation is frequently employed in various international markets, often positioned for both pediatric and adult patient groups.

The medicine contains two active, synthetic ingredients: Lidocaine Hydrochloride, which is an amide local anesthetic, and Phenazone (Antipyrine), a pyrazolone derivative noted for its analgesic and anti-inflammatory properties. The specific blend of a fast-acting anesthetic and a longer-duration analgesic is clinically recognized for providing effective symptomatic relief. As an Otic Solution, the components are dissolved in a suitable hydrophilic solvent base, such as glycerol, designed for direct instillation into the ear canal.

Pharmacological Classification and General Purpose

The pharmacological classification establishes Otipax L within the category of Topical Otic Preparations used for pain management. The combination of components is widely recognized for treating localized discomfort.

The general purpose of the medicine is to provide symptomatic relief for localized discomfort in the ear structure, such as that experienced during episodes of painful, non-perforated otitis media. The efficacy of local anesthetics in rapidly interrupting nerve pain signals at the application site is a recognized mechanism for providing comfort. This means the medicine offers quick, focused relief by numbing the painful area directly. The preparation achieves this benefit by combining a local anesthetic agent and an analgesic compound, focusing on focused, symptomatic intervention.

Regulatory References

  1. Lidocaine - StatPearls - NCBI Bookshelf

What side effects are possible with Otipax L?

Possible Side Effects and Safety Information

The safety profile of Otipax L is primarily defined by its topical, non-systemic administration route, meaning adverse effects are largely concentrated at the site of application. The information presented here reflects official classifications from government regulatory documents.

Officially Documented Adverse Reactions

Adverse effects observed with this otic solution are generally localized and pertain to the ear structure or the skin around the application site. These are often classified as Not known in frequency, as precise incidence rates cannot be reliably estimated from available post-marketing data for topical medicines.

System-Organ Class Examples of Documented Reactions
Ear and Labyrinth Disorders Localized irritation, discomfort, or stinging at the application site.
Skin and Subcutaneous Tissue Disorders Local allergic reactions, pruritus (itching), or hyperaemia (localized redness).
Immune System Disorders Hypersensitivity reactions (both local and, rarely, systemic).

Critical Safety Constraints and Limitations

The most critical constraint in the regulatory documents is the absolute contraindication against use if the tympanic membrane (eardrum) is known or suspected to be perforated. This restriction is necessary to prevent the active ingredients from reaching the inner ear, which could lead to potential toxicity. The medication is also restricted in individuals with known hypersensitivity to the active substances, Lidocaine Hydrochloride or Phenazone, or to related pyrazolone or amide-type local anesthetic compounds.

No unique adverse reaction patterns are typically specified for special populations like older adults or those with renal or hepatic impairment, given the minimal systemic absorption from proper topical use. The official safety data confirms that the profile is dominated by local effects and administrative limitations, consistent with its design as a non-systemic intervention.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory classification for the intended use of this otic solution deems the risk of overdose to be minimal or not applicable when the tympanic membrane (eardrum) is intact. This assessment is based on the negligible systemic absorption of the active ingredients through the ear canal in normal conditions.

However, a serious overdose may occur if the medicine is accidentally swallowed or if it is administered into an ear with a perforated eardrum, leading to excessive systemic absorption. In such cases, the manifestations are consistent with the toxicities of the active components, Lidocaine and Phenazone. These symptoms may initially present as lightheadedness, dizziness, or tremors stemming from Central Nervous System (CNS) effects. Severe, life-threatening outcomes can include convulsions, profound hypotension, cardiovascular collapse, or respiratory arrest.

A serious complication noted in regulatory documents is the potential for Methemoglobinemia, a blood disorder, which is particularly relevant in infants under six months of age and patients with G6PD deficiency.

In any case of accidental ingestion or the onset of severe systemic symptoms, immediate medical attention is required. Officially documented management includes the monitoring of cardiovascular and respiratory vital signs and the administration of specific supportive treatments, such as Methylene blue for severe Methemoglobinemia. Contacting a doctor or poison control center right away is the mandated emergency action.

Therapeutic Uses of Otipax L

What Otipax L Treats: Main Uses and Benefits

Otipax L is primarily used to provide local symptomatic relief for ear pain (otalgia) and the associated discomfort from swelling within the ear structure. It is applied across domains where additional symptomatic support is needed, and is relevant in contexts marked by increased discomfort or tension. The use for local symptomatic treatment in specific ear conditions is consistent with its intended pharmaceutical application.

The medicine is commonly used across conditions presenting with acute episodes, such as certain forms of congestive acute otitis media and barotrauma (ear pain due to pressure changes).

“The medication may be relevant when supportive symptom management is appropriate during acute or disruptive episodes.”

This medication targets acute, localized symptoms related to inflammatory or irritative states, such as the intense, throbbing, or sharp discomfort often felt deep inside the ear. It is generally applied in clinical settings that involve acute or unstable symptom patterns, when short-term symptomatic assistance is needed. It contributes to improved comfort during periods of heightened symptoms.

Quick Fact

Symptomatic Relief for Acute Ear Pain (Otalgia)

It supports patients during difficult episodes by easing distress, and assists with maintaining functional stability.

Regulatory References

  1. Food And Drugs Authority (Ghana) document for Otipax

Eligibility and Restrictions for Use

Who can and cannot use Otipax L?

Eligibility for Otipax L (Phenazone/Lidocaine otic solution) is strictly determined by its official regulatory labeling, focusing on contraindications and mandated cautions.

Absolute Contraindications

The medicine must not be used by certain populations, primarily due to the risk of systemic exposure or allergic reaction:

  • Tympanic Perforation: Patients with a perforated or burst eardrum must not use this medicine. This is the most critical exclusion as the eardrum integrity prevents the topical solution from entering the middle ear.
  • Hypersensitivity: Individuals with known allergy to the active substances (Phenazone, Lidocaine Hydrochloride), amide-type local anesthetics, or any other excipient.

Age and Conditional Eligibility

Population Group Regulatory Status
Infants under 3 months Caution required due to potential susceptibility to methemoglobinemia.
Children & Adults Approved for use under standard labeled conditions.
Pregnant/Lactating Women Generally permitted, as systemic exposure is considered negligible.
G6PD/Haemoglobinopathies Caution required due to underlying susceptibility to methemoglobinemia.
Athletes Cautioned as Phenazone may produce a positive result in anti-doping tests.

No specific restrictions related to renal or hepatic impairment are documented, reflecting the medicine's topical route of administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Otipax L (phenazone and lidocaine hydrochloride otic solution) consistently defines its interaction profile by its non-systemic route of administration and minimal absorption when used correctly. As a result, the regulatory labels state that no clinically significant interactions are known to occur with other medicinal products.

Interaction Status Summary

Category Regulatory Documentation Status
Drug-Drug Interactions None documented (not clinically significant)
Metabolic/CYP Interactions None documented
Food, Alcohol, Supplements None documented

Interaction-Related Restrictions

The most significant interaction-related consideration noted in official documentation is tied to the physical condition of the ear. The medicine carries a risk of increased systemic exposure of the active ingredients if it is administered in the presence of a perforated tympanic membrane (eardrum). This condition alters the drug's intended localized pharmacokinetics, allowing the ingredients to enter the systemic circulation, which is otherwise prevented by the intact eardrum. Official prescribing information does not specify timing separation requirements for administration with other medicines or substances.

Mechanism of Action

Direct Blockade of Peripheral Nerve Signaling

Otipax L functions via a dual mechanism targeting both electrical signal transmission and local chemical mediators. The Lidocaine component acts directly on voltage-gated sodium channels of peripheral sensory nerve fibers, which are essential for propagating nerve impulses. Lidocaine physically blocks these channels, preventing the necessary ion influx. This mechanism leads to an immediate, reversible functional silence of the nerve, thereby inducing local neural conduction block.

Modulation of Local Inflammatory Mediators

The second component, Phenazone, acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme. This enzymatic inhibition reduces the local biosynthesis of prostaglandins, which are key mediators in the local inflammatory response and peripheral sensitization. This process contributes to the extended modulation of the local inflammatory response.

Synergistic Peripheral Mechanism

These two distinct mechanisms act upon the nociceptive signaling cascade. Lidocaine's mechanism dictates the rapid speed of target engagement through electrical conduction blockade, and Phenazone's mechanism contributes to the extended time course of the effect by modulating local chemical mediators. The entire mechanism is strictly peripheral, focused entirely on local tissue structures and not involving central nervous system modulation.

Dosage and Administration Information

How to use Otipax L: Official Administration Guidelines

This section provides information on the standard administration of Otipax L (phenazone and lidocaine hydrochloride), focusing on the procedural steps and dosing for proper use.

Administration Details

Feature Instruction
Route of Administration Auricular route (instillation into the auditory meatus).
Dosing Schedule 4 drops in the painful ear.
Frequency 2 or 3 times a day.
Treatment Duration Limit treatment duration to a maximum of 10 days. A medical review is required after this period.
Age-Group Rules The dosage (4 drops) is the same for adults and children.
Crucial Precaution Administration is strictly conditional upon the integrity of the tympanic membrane being ensured by a medical examination prior to use.

Procedural Steps

  1. Warm the container (bottle) between the hands prior to use. This step is required to prevent the unpleasant sensation of cold liquid coming into contact with the ear.
  2. Unscrew the cap of the bottle and screw on the dropper (if provided separately).
  3. Remove the dropper's cap.
  4. Instil 4 drops of the solution into the auditory canal of the affected ear.
  5. Apply the drops by turning the bottle upside down and applying gentle pressure to the soft part of the dropper.
  6. Close the dropper tightly after each use.

Missed Dose Guidance

If a dose is missed, administer it as soon as the omission is noticed. However, if the time for the next scheduled dose is near, skip the missed dose and resume the normal dosing schedule. Do not administer a double dose to compensate for the forgotten one.

Recent Clinical Evidence

Research evidence / Overview of Studies for Otipax L

Evidence for Use in Acute Otitis Media (AOM) Pain Relief

Otipax L was studied for localized symptom relief in research exploring how discomfort changes over time in acute otitis media (AOM). This condition is characterized by conditions involving periods of heightened symptoms, and studies aimed to evaluate outcomes related to physical discomfort in the ear. The research base includes systematic reviews, as well as several randomized controlled trials (RCTs). These trials primarily compared the drops against a dummy (placebo) drop or compared the drops used alongside systemic oral analgesics against the systemic oral analgesics alone.

Studies explored the topical solution on patient-reported outcomes describing perceived discomfort. Researchers primarily monitored changes in ear pain scores over defined time intervals following administration. Findings describe patterns observed in the studies where initial pain scores were observed to change shortly after the application, with some research highlighting rapid changes measured during the study period.

Evidence in Pediatric and Special Populations

Research examining Otipax L has primarily involved pediatric populations, as the condition of acute otitis media is most common in children. Studies monitored populations ranging from infants (over six months old) to adolescents. Results apply only to the populations studied, meaning the majority of the current evidence is confined to children with a clinically diagnosed acute ear infection who also had an intact eardrum.

Uncertainty and Research Gaps in the Evidence

One area of uncertainty relates to how much the drops were observed to change pain scores when patients were already receiving standard oral pain medication. Findings were mixed regarding the comparative measurements against placebo drops when both groups were also taking systemic analgesics. Additionally, the follow-up durations were limited, and evidence quality varies across studies, with several key trials having modest sample sizes. This means that while studies provide insight into short-term changes, the long-term effects are not fully established, and comparative evidence is limited when assessed against some other symptom management approaches.

Key Studies & References

  1. 2021 exceptional surveillance of otitis media (acute): antimicrobial prescribing (NICE guideline NG91)

How should Otipax L be stored and disposed of?

How to Store and Dispose of Otipax L?

This section outlines the official requirements for storing, handling, and disposing of the otic solution, as documented in regulatory labeling.

Official Storage Requirements

Storage Factor Mandate
Temperature Store at a temperature below 30 C (86 F).
Protection Store in the original package to protect from light. Do not freeze.
Container Keep the bottle cap tightly closed after each use.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

  • In-Use Stability: The solution must be discarded 30 days after the bottle is first opened.
  • Disposal: Unused or expired product must be disposed of in accordance with local requirements. It should not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSlovakia

Equivalent of Otipax L found in:

A-Z Index: